Jim Simons Travere Therapeutics, Inc. Transaction History
Renaissance Technologies LLC
- $63.1 Billion
- Q3 2024
A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,875,014 shares of TVTX stock, worth $36.7 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
1,875,014
Previous 2,203,814
14.92%
Holding current value
$36.7 Million
Previous $18.1 Million
44.8%
% of portfolio
0.04%
Previous 0.03%
Shares
16 transactions
Others Institutions Holding TVTX
# of Institutions
193Shares Held
84.6MCall Options Held
776KPut Options Held
900K-
Armistice Capital, LLC New York, NY7.65MShares$150 Million1.78% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$150 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.9MShares$135 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.68MShares$91.7 Million2.23% of portfolio
-
Woodline Partners LP San Francisco, CA4.34MShares$84.9 Million0.55% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.26B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...